<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Greater risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Greater risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
